TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Tuesday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Down 1.0 %

Shares of TXMD stock opened at $2.01 on Tuesday. The stock has a fifty day moving average price of $2.15 and a 200 day moving average price of $2.26. TherapeuticsMD has a one year low of $1.84 and a one year high of $4.72.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new position in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned approximately 0.21% of TherapeuticsMD at the end of the most recent reporting period. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.